Live Analyst Rating Changes 1525 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Caitlin Cronin
CG
Caitlin Cronin
Canaccord Genuity
Wall Street Analyst
★★☆☆☆
#1825
on 13Foresight · ranked by our own returns
38%
Success Rate
+7.2%
Average Return
6 of 16 calls profitable · -5.3% vs benchmark
📈 Across the calls we could measure, roughly 38% of Caitlin Cronin's ratings turned a profit when each position was held for 1 year — averaging +7.2% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

31 Buy 13 Hold 0 Sell
Caitlin's Stock Coverage 15 ratings · 2026-06-20
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return
GMED
Globus Medical
 May 08, 2026 BUY Strong Buy
+21.0% avg upside
24 analysts
$115.00
45.17% Upside
 +3.1%
ZBH
Zimmer Biomet Holdings
 Apr 24, 2026 HOLD Buy
+27.6% avg upside
37 analysts
$93.00
5.64% Upside
 -2.7%
ENOV
Enovis
 Feb 27, 2026 BUY Strong Buy
+216.5% avg upside
37 analysts
$50.00
127.68% Upside
 -2.3%
BVS
Bioventus
 Dec 17, 2025 BUY Strong Buy
+41.0% avg upside
8 analysts
$15.00
72.17% Upside
 +11.3%
OFIX
Orthofix Medical
 Dec 16, 2025 BUY Strong Buy
+207.1% avg upside
15 analysts
$24.00
153.92% Upside
 -21.0%
TELA
TELA Bio
 Dec 16, 2025 BUY Strong Buy
+1023.6% avg upside
8 analysts
$4.00
399.28% Upside
 -16.1%
VCEL
Vericel
 Nov 06, 2025 BUY Strong Buy
+13.9% avg upside
16 analysts
$58.00
44.63% Upside
 -14.8%
SYK
Stryker
 Oct 31, 2025 BUY Strong Buy
+24.0% avg upside
36 analysts
$435.00
41.27% Upside
 -15.0%
ATEC
Alphatec Holdings
 Oct 31, 2025 BUY Strong Buy
+112.9% avg upside
22 analysts
$25.00
183.85% Upside
 -57.4%
INMD
InMode
 Oct 10, 2025 HOLD Buy
+41.7% avg upside
9 analysts
$16.00
19.44% Upside
 -12.5%
KRMD
REPRO-MED Systems
 Sep 18, 2025 BUY Strong Buy
+65.0% avg upside
9 analysts
$5.00
28.26% Upside
 +2.5%
AXGN
AxoGen
 Aug 25, 2025 BUY Strong Buy
-25.7% avg upside
21 analysts
$24.00
46.45% Downside
 +201.3%
SNN
Smith & Nephew Snats
 Aug 18, 2025 HOLD Buy
+11.8% avg upside
14 analysts
$36.00
19.61% Upside
 -17.9%
SIBN
SI-Bone
 Aug 13, 2025 BUY Strong Buy
+60.4% avg upside
18 analysts
$26.00
64.13% Upside
 -9.8%
RBOT
Vicarious Surgical
 Nov 13, 2023 HOLD Buy
+5334.8% avg upside
6 analysts
$12.00
5117.47% Upside
 +64.7%
🔒 10 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Caitlin Cronin — Frequently Asked Questions
How accurate are Caitlin Cronin's stock ratings?
Based on the calls 13Foresight could measure, about 38% of Caitlin's ratings were profitable over a one-year hold, with an average return of +7.3% per rating, or -5.1% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Caitlin ranked on 13Foresight?
Caitlin Cronin is currently ranked #1825 with a 2-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Caitlin cover?
Caitlin most recently has ratings on GMED, ZBH, ENOV, BVS, OFIX, TELA, VCEL, SYK, ATEC, INMD, KRMD, AXGN and 3 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.